|
|
Volumn 13, Issue 3, 2014, Pages 162-164
|
|
Kinase inhibitors overachieve in CLL
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRUTON TYROSINE KINASE;
BRUTON TYROSINE KINASE INHIBITOR;
CC 292;
IBRUTINIB;
IDELALISIB;
PHOSPHATIDYLINOSITOL 3 KINASE;
UNCLASSIFIED DRUG;
CANCER IMMUNOTHERAPY;
CHRONIC LYMPHATIC LEUKEMIA;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
MOLECULARLY TARGETED THERAPY;
NOTE;
PHARMACEUTICAL CARE;
PRIORITY JOURNAL;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
ANIMALS;
BICYCLO COMPOUNDS, HETEROCYCLIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
PROTEIN KINASE INHIBITORS;
PURINES;
QUINAZOLINONES;
SULFONAMIDES;
|
|
EID: 84895803751
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4259 Document Type: Note |
|
Times cited : (17)
|
|
References (0)
|
